Reviewer's report

Title: Pathological complete response in advanced gastric stromal tumour after imatinib mesylate therapy: A case report

Version: 1 Date: 23 August 2010

Reviewer: christophe CT tournigand

Which of the following following best describes what type of case report this is?: An unexpected event in the course of observing or treating a patient

Has the case been reported coherently?: Yes

Is the case report authentic?: Yes

Is the case report ethical?: Yes

Is there any missing information that you think must be added before publication?: Yes

Is this case worth reporting?: Yes

Is the case report persuasive?: Yes

Does the case report have explanatory value?: Yes

Does the case report have diagnostic value?: No

Will the case report make a difference to clinical practice?: No

Is the anonymity of the patient protected?: Yes

Comments to authors:

The case presented of pathological complete response with imatinib in a GIST is rather unusual and interesting. However, major responses are frequent and IM is indicated in inoperable GIST. Authors should emphasize this point: page 5, line 7, authors should recognize that IM in inoperable or locally advanced GIST is already a recommandation from guidelines like NCCN and ESMO.

Other comment: the case would be even more interesting with the result of the kit mutation analysis. please provide if available.

Minor comments:
abstract line 4 : "...studies is above 50%..."
abstract conclusion line 4 : define IM
abstract conclusion line 5 : "high sensitivity"
Page 4, line 18 : the patient received
Page 5, line 2 : the patient received
Page 5, line 13 : exon 11 mutation
Page 5 line 17 : clinical benefit

**Quality of written English:** Needs some language corrections before being published